Therapeutic potential of anti-MOSPD2 monoclonal antibodies

Human proof-of-concept data showed that 2 monoclonal antibodies against motile sperm domain-containing protein 2 (MOSPD2) significantly inhibit the migration of monocytes from MS patients ex vivo, regardless of patient diagnosis, disease severity, or treatment applied [1]. Anti-MOSPD2 monoclonal antibodies, therefore, hold therapeutic potential for MS in all stages. MOSPD2 is a surface protein expressed on monocytes and plays a key role in these cells’ ability to migrate to inflammatory sites, in a chemokine-agnostic manner. Study results of 2 anti-MOSPD2 monoclonal antibodies with distinct epitopes were presented. Blood samples from 25 relapsing-remitting, 4 primary progressive, and 4 secondary-progressive MS patients were analysed. Isolated monocytes were tested for chemotaxis in the presence of 2 anti-MOSPD2 drug candidates, here referred to as mAb1 and mAb2. An isotype control antibody was used as a reference. Incubation with mAb...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 25 November, 2020